Emerging in the arena of obesity treatment, retatrutide presents a distinct approach. Beyond many available medications, retatrutide functions as a double agonist, at once targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. This concurrent engagement fosters various advantageous effects, incl